|
16 Companies |
|
12 Products |
|
12 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
31 News |
|
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P1/2
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 4, 2018
P2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P1/2 Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 2, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018 Trial completion date: Apr 2018 --> Apr 2019
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 31, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2018 --> Apr 2019 Phase classification: P1 --> P2
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 25, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P2 Trial primary completion date: Jan 2019 --> Apr 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 5, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2019 --> Apr 2018 Trial primary completion date: Jan 2018 --> Jan 2019
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 30, 2017
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2018 --> Jan 2019 Trial primary completion date: Jan 2017 --> Jan 2018
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Feb 8, 2016
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Jan 2016 --> Jan 2017
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion: A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer (clinicaltrials.gov) - Jun 30, 2015
P2, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Apr 20, 2015
P1, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Feb 6, 2015
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial termination, Trial primary completion date: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Dec 24, 2014
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2015 --> Jan 2016 N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 6, 2014
P1, N=14, Completed, Sponsor: Michael Morse, MD
N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009 No longer recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Enrollment change, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Mar 25, 2014
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=27 --> 33
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion, Metastases: Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=61, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=27 --> 33 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Surgery, Post-surgery: Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=48, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Suspended --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, NN1213 / Novo Nordisk
Trial completion, Metastases: Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed No longer recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Enrollment closed, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Dec 5, 2013
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Jun 30, 2013
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=25 --> 48
- Leukine (sargramostim) / Partner Therap
Trial termination, Combination therapy: Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer (clinicaltrials.gov) - May 14, 2013
P1, N=42, Terminated, Sponsor: National Cancer Institute (NCI)
N=25 --> 48 Completed --> Terminated
- Trial termination, Metastases: Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) (clinicaltrials.gov) - Jan 22, 2013
P2, N=86, Terminated, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Completed --> Terminated; Administratively complete.
- Leukine (sargramostim) / Partner Therap
Enrollment change: Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (clinicaltrials.gov) - Jan 1, 2013
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Administratively complete. N=21 --> 42
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment change, Metastases: Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer (clinicaltrials.gov) - Nov 7, 2012
P1, N=24, Completed, Sponsor: H. Kim Lyerly
N=21 --> 42 N=12 --> 24
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion, Metastases: Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer (clinicaltrials.gov) - Nov 7, 2012
P1, N=24, Completed, Sponsor: H. Kim Lyerly
N=12 --> 24 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Apr 9, 2012
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion, Enrollment change: A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy (clinicaltrials.gov) - Aug 8, 2011
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=30 --> 21 | Recruiting --> Completed
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion: A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy (clinicaltrials.gov) - Aug 8, 2011
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 21 | Recruiting --> Completed Recruiting --> Completed